




RealRate

PHARMACEUTICAL 2022

Intercept Pharmaceuticals INC
Rank 422 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Intercept Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Intercept Pharmaceuticals INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 11% points. The greatest weakness of Intercept Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 189% points.

The company's Economic Capital Ratio, given in the ranking table, is 134%, being 141% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	502,292
Cost of Goods Sold	3,100
Intangible Assets	0
Liabilities, Current	166,817
Liabilities, Non-Current	544,168
Other Assets	21,354
Other Compr. Net Income	-396
Other Expenses	-86
Other Liabilities	0
Other Net Income	-35,753
Other Revenues	363,468
Property and Equipment	3,377
Research and Development	185,272
Selling, General and Administrative Expense	230,855

Output Variable	Value in 1000 USD
Assets	527,023
Liabilities	710,985
Expenses	419,141
Revenues	363,468
Stockholders Equity	-183,962
Net Income	-91,426
Comprehensive Net Income	-91,624
BaseVar	1,028,383
ECR before LimitedLiability	-80%
Economic Capital Ratio	134%